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Abstract
Atherosclerosis is considered as an inflammatory and chronic disorder with an important immunologic component,
which underlies the majority of cardiovascular diseases; condition that belongs to a group of noncommunicable
diseases that to date and despite of prevention and treatment approaches, they remain as the main cause of death
worldwide, with 17.5 million of deaths every year. The impact of lipids in human health and disease is taking center
stage in research, due to lipotoxicity explained by elevated concentration of circulating lipids, in addition to altered
adipose tissue metabolism, and aberrant intracellular signaling. Immune response and metabolic regulation are
highly integrated systems and the proper function of each one is dependent on the other. B lymphocytes express
a variety of receptors that can recognize foreign, endogenous or modified self-antigens, among them oxidized low
density lipoproteins, which are the main antigens in atherosclerosis. Mechanisms of B cells to recognize, remove
and present lipids are not completely clear. However, it has been reported that B cell can recognize/remove lipids
through a range of receptors, such as LDLR, CD1d, FcR and SR, which might have an atheroprotector or proatherogenic
role during the course of atherosclerotic disease. Pertinent literature related to these receptors was examined to inform
the present conclusions.
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Background
Cardiovascular diseases (CVDs) belong to a group of
noncommunicable diseases (NCDs) that to date and des-
pite of prevention and treatment approaches, they re-
main as the main cause of death worldwide [1, 2].
Atherosclerosis is considered as an inflammatory and
chronic disorder with an important immunologic com-
ponent, which underlies the majority of CVDs [3–5].
This process is favored by inadequate life styles like the
use of cigarette, physical inactivity, unhealthy diets,
harmful use of alcohol and in some cases even genetic
susceptibilities; leading to metabolic changes and pro-
moting the development of other kind of conditions like
hypertension, dyslipidemia, overweight and diabetes,
which constitute comorbidities of the so called “meta-
bolic syndrome” (MetS) [6–8].
In 1998 the first formal definition of MetS was pub-
lished by the World Health Organization (WHO) which
specifies that besides insulin resistance, that results to be
the major underlying risk factor of the MetS, two
additional risk factors are necessary for MetS diagnosis,
such as obesity, hypertension, high triglyceride levels,
reduced high-density lipoprotein (HDL) levels, or micro-
albuminuria. However, the latest reported definition,
communicated by representatives of the International
Diabetes Federation; National Heart, Lung and Blood
Institute; American Heart Association among others in
2009, considers abdominal obesity as a mandatory re-
quirement for the diagnosis of MetS, including the pres-
ence of any of the three risk factors among the five
previously described [9–14].
MetS is about dysregulation of a wide range of param-
eters that easily disrupt the immunological balance,
through unhealthy behavioral patterns that lead to phys-
iopathological changes, a similar case to CVD. The im-
pact of lipids in human health and disease is taking
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center stage in research [15], due to lipotoxicity ex-
plained by elevated concentration of circulating lipids in
non-adipose tissue, in addition to altered adipose tissue
metabolism, and aberrant intracellular signaling [16].
Indeed, unbalanced production of pro and anti-
inflammatory adipokines, as well as the participation of
many cells of the immune system, contribute to the
development of MetS, which also constitute specific
features of CVD [17].
Immune response and metabolic regulation are highly
integrated systems and the proper function of each one
is dependent on the other. Dysfunction of these central
homeostatic mechanisms can lead to a cluster of chronic
metabolic disorders, characterized by “chronic inflam-
mation”, which drives to a sustained interaction between
parenchymal and stromal cells in response to exogenous
and endogenous stress, ending in tissue dysfunction and
remodeling [17–19]. Among this group of disorders we
can find obesity, type 2 diabetes and CVD [17, 20]. In
2014, the WHO reported that NCDs continue to be the
global leading cause of death; with a 46.2% associated to
CVDs, representing 17.5 million deaths every year.
Diabetes caused an additional 1.5 million of deaths, and
it is estimated that for 2030, close to 400 million people
worldwide will be affected by this disease, with 90% of
these being type 2 diabetes [2, 21, 22]. Likewise, the
WHO estimates that more than one billion adults world-
wide are overweight, from which 300 million are clinic-
ally obese [23]. Since their projections show that NCDs
will be responsible for a significant increase in the total
number of deaths in the next decade, these chronic
inflammatory diseases that involve lipid metabolism dys-
regulation are a matter of public health concern [21].
Studies of tissue morphology and transcriptional pro-
filing in several obesity animal models as well as in
obese subjects, have shown that the development of in-
sulin resistance is related to adipose tissue remodeling,
which involves cellular infiltration of macrophages indu-
cing inflammatory pathways and ectopic lipid accumula-
tion [24–26]. In this sense it was demonstrated that
even modest levels of overweight/obesity elicit modifica-
tions in adipose tissue immune function [27].
Recently, it has been reported that early B and T
lymphocyte trafficking and infiltration, could promote
initiation and perpetuation of adipose tissue inflam-
mation [28–30]. Winer et al. reported that in diet in-
duced obese (DIO) mice, the depletion of early B
cells (which currently accumulate in this model), by
anti-CD20 treatment, could protect from insulin re-
sistance despite weight gain; while transfer of DIO-
IgG exacerbated the metabolic disease. This suggests
that B cells contribute to insulin resistance probably
by mechanisms such as antigen presentation to T
cells, secreting inflammatory cytokines and/or
producing pathogenic antibodies [22, 31]. Also, in dia-
betes mellitus patients, alterations of B cell toll like
receptor (TLR) function have been described favoring
inflammation, by increased expression of surface
TLR4, elevation of pro-inflammatory IL8, and de-
creased levels of the anti-inflammatory/protective
cytokine IL10 [32]. In fact in 2002, the Leiden 85-
Plus study found a direct association between the
decreased IL10 levels, type 2 diabetes and MetS [33].
In parallel, B cell activation is usually detected in
both inherited (e.g., Gaucher disease) [34], and
acquired lipid metabolism disorders such as athero-
sclerosis, in which its participation is contradictory.
Some results showed increased atherosclerosis in B
cell deficient LDL receptor-deficient (Ldlr−/−) mice,
suggesting an atheroprotector role, whereas others
have reported that the depletion of B cells through
the use of specific monoclonal antibodies against
CD20 molecule, reduce the development of athero-
sclerosis in both, apolipoprotein E single knockout
(Apoe−/−) and Ldlr−/− mice, showing an atherogenic
effect [35, 36].
B lymphocytes express a variety of receptors that
recognize foreign, endogenous or modified self-antigens,
among them oxidized low density lipoproteins (oxLDL),
which are the main antigens in atherosclerosis. B cell
mechanisms to recognize, remove and present lipids are
not completely clear. However, it has been reported that
B cells can remove lipid antigens through a B cell recep-
tor (BCR) dependent via, but also there is internalization
and antigen presentation to invariant natural killer T
(iNKT) cells by BCR independent via, associated to low
density lipoprotein receptor (LDLR) expression on acti-
vated B cells [37–41].
CD1 is included among the receptors expressed in B
cells that have the ability to present lipid antigens. They
belong to β2 microglobulin family associated polypep-
tides, which relate with the major histocompatibility
complex (MHC) class I and II. Also, B cells express Fc
receptors (FcR), which through their immunoreceptor
tyrosine-based activation or inhibitory motifs (ITAMs or
ITIMs) initiate and propagate early signaling events
leading to cell-specific responses [42], and scavenger
receptors (SR), which belong to the family of pattern
recognition receptors (PRR), that recognize pathogen
associated molecular patterns (PAMPs), as well as modi-
fied antigens, such as death associated molecular
patterns (DAMPs), including modified host derived mol-
ecules like oxLDL [43, 44] (Table 1).
The disruption of cellular homeostasis through oxida-
tive stress and contribution to cell death by generation
of toxic intermediates during aberrant lipid metabolism,
and enhanced pro-inflammatory immunological path-
ways, could occur in vascular, cardiac and adipose tissue
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Table 1 Receptors involved in lipid recognition-removal or presentation and immune responses in experimental atherosclerotic
disease
Receptor Described Mechanism Receptor
Subclass







or presentation by B cells
LDLR Internalization of LDL
through LDLR, to
transfer cholesterol
from plasma LDL into
the cell in a controlled
manner.
A defect in the expression or
internalization of LDLR leads to
an increase in circulating plasma
LDL, predisposing them to
oxidation, condition that
contributes in a great manner









FcμR High titers of anti-oxLDL IgM in
Apoe−/− mice fed a high fat diet.
Undetermined [58, 59]
FcγRIIB Deficiency in the γ chain
expression of FcγR in Apoe−/−
mice fed with high fat diet,
is related with a limited
development and progression
of atherosclerosis that could be
associated with the loss of
FcγRI and FcγRIIIA, and the
overexpression of the inhibitory
FcγRIIB characteristic of this
mouse model.
Atheroprotector [69, 70]




as well as increased activation
and expansion of B cells.
Undetermined [71]




as well as increased activation
and expansion of B cells.
[72]
SR Recognition of several





to the outcome of the
immune system responses.
CD36 The absence of CD36 protects
against atherosclerotic lesion
development in Apoe−/− mice,
which approximately developed
just a 20% of lesion assessed
by en face analysis of whole






levels and larger atherosclerotic
lesions located in aortic sinus
compared with Apoe−/− mice as
controls, suggesting that SR
mediated lipid uptake protected
against atherosclerosis lesion
formation rather than promote it.
Atheroprotector [88]
Aortic lesion analysis in Ldlr−/−
CD36−/− mice fed with western
diet and Ldlr−/− mice revealed
no difference between the
groups, however bone marrow
transplant from Ldlr-CD36−/−
into Apoe−/− mice had 38.4%
less lesion area compared with
those receiving Ldlr−/− transplant.
Proatherogenic [89]
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diseases. This opens up the possibility that immune cells
often interacting with oxidized products, and more spe-
cifically B cells, could participate in the process of lipo-
toxicity at the injured areas during the tissue remodeling
process, leading to development and establishment of
the disease or even regulating the inflammatory process.
This supports the importance of understanding the re-
ceptors that could be involved in lipids recognition and/
or removal by B cells.
Receptors involved in lipids recognition-removal
by B cells
LDLR
Lymphocytes obtain cholesterol from serum low density
lipoproteins (LDL) through its specific LDLR, which is
internalized along with LDL; since these cells do not
synthetize enough cholesterol to support their mem-
branes [45–47]. The main function of this mechanism is
to transfer cholesterol from plasma LDL into the cell in
a controlled manner [48]. LDL endocytosis and subse-
quent lysosomal degradation induces the release of free
cholesterol, which suppresses 3-hydroxy-3-methyl-gluta-
ryl-CoA reductase (HMG-CoA) activity, stimulates acyl-
CoA cholesterol acyltransferase (ACAT) and regulates
the LDLR activity by a feedback mechanism [49, 50].
LDLR is widely expressed in different cell types, in-
cluding T and B lymphocytes [51]. However there are
important differences in cholesterol metabolism among
these lymphocyte subpopulations; for example the con-
tent of both, free and ester cholesterol is slightly lower
in B cells than in T cells. In fact, a conclusion of a study
more than two decades ago, pointed out that B cells had
deficient LDL catabolism compared with T cells, in terms
of internalization of LDLR-LDL complex [52]. However,
recently it has been reported that B lymphocytes purified
from peripheral blood express LDLR, and are able to
internalize LDL with a four-fold increase in the expression
of this receptor compared with non-stimulated T and NKT
cells. Also, an up regulation of this receptor has been re-
ported after B cell activation through stimulation with dif-
ferent concentrations of IL2 or pokeweed mitogen, which
could suggest that LDL internalization could be important
for B cells metabolism and maybe even immunoglobulin
(Ig) production [51]. Additionally, besides the cell type,
some hormones may play a role in the regulation of LDLR
activity, such as insulin, which decreases LDL metabolism
in lymphocytes by lowering its binding to LDL receptor,
with a consequent decreased internalization and degrad-
ation of LDL [48]. This is evident in secondary hypercho-
lesterolemias of endocrine origin, and in diabetes, in which
the lack of insulin increases the levels of triglycerides, very
low density lipoproteins (VLDL) and LDL [53].
It is clear that a defect in the expression or internaliza-
tion of LDLR leads to an increase in circulating plasma
LDL, predisposing it to oxidation, condition that con-
tributes in a great manner to the physiopathology of ath-
erosclerosis [54]. Finally, it is also important to highlight
that LDL removal through LDLR might be relevant not
only for B cell metabolism, but also for LDL antigen
presentation, which could participate in the inflamma-
tory process observed in atherosclerosis [55].
FcR
A critical role for FcR has been described in B cell
survival following antigen presentation [56], and in an
enhanced antibody response to antigenic challenge [57].
Table 1 Receptors involved in lipid recognition-removal or presentation and immune responses in experimental atherosclerotic
disease (Continued)
SR-BI SRBI−/−Apoe−/− mice fed with
standard chow diet developed
occlusive coronary artery
atherosclerosis as well as
significant atherosclerotic
lesions, compared with control
mice.
Atheroprotector [95–97]
Transplantation of bone marrow
from SR-BI−/− mice into Ldlr−/−
mice, induced a twofold
reduction of the mean
atherosclerotic lesion area
after 4 weeks of high fat diet.
Proatherogenic [98]
CD1 Presentation of lipid antigens
or hydrophobic peptide
antigens to T cells, activating
a specialized T cell subset
called invariant NKT cells (iNKT),
and leading to immune
responses that contribute
with the inflammatory process.
CD1d CD1d−/−Ldlr−/− mice present
a 50% reduction in lesion
formation compared with
controls, but the influence
on lesion progression is just
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Although FcRs are not directly involved in lipids re-
moval, they could indirectly participate in this process,
due to their capability to recognize Ig directed to modi-
fied lipids. In this sense, immunological system has the
ability to recognize and respond effectively to neoepi-
topes formed by lipid peroxidation [58]. This includes
natural antibodies, which bind to oxidized phospholipids
contained in oxLDL. The importance of these antibodies
in the context of diseases with a lipid component is
evidenced by the observation that in the Apoe−/− athero-
sclerosis model, mice fed with high fat diet (HFD)
present high titers of anti-oxLDL IgM [59].
However, FcμR is not the only FcR expressed on B
cells; actually the most widely expressed is the FcγRIIB.
FcγR, are important cell surface effector molecules that
bind the Fc portion of IgG. In mice, four classes of FcγRs
have been identified, FcγRI, FcγRIIB, FcγRIII and
FcγRIV, and three of them may interact with immune
complexes, such as FcγRI, FcγRIII, and FcγRIIB [60].
This last molecule contains an ITIM in its cytoplasmic
tail, leading to negative regulation of BCR signaling
affecting B cell activation and differentiation [61–63].
In humans, FcγRIIA and FcγRIIB conform the FcγRII
subfamily, and in both cases they bind the Fc portion of
IgG with low affinity [64]. FcγRs are differentially expressed
in human leukocytes. Both isoforms of CD32, respectively
the activating and inhibitory members are expressed in B
cells, dependent on its activation status [65]. FcγRI (CD64)
and FcγRIIA (CD32) are highly expressed on monocytes,
macrophages, and granulocytes, whereas FcγRIIIA (CD16)
mainly in macrophages and a small subset of monocytes,
as well as in smooth muscle cells and endothelial cells,
which also express FcγRIIA [66], and finally FcγRIIIB
which is expressed on granulocytes [67, 68].
Apoe−/−mice with a deficiency in the γ chain expression
of FcγR, and fed with high fat diet, exhibited a limited de-
velopment and progression of atherosclerosis, suggesting
a proatherogenic effect that could be associated with the
loss of FcγRI and FcγRIIIA, and the overexpression of the
inhibitory FcγRIIB characteristic of this mouse model.
These mice also showed a ∼ 50% less atherosclerotic lesion
as well as reduced expression of inflammatory molecules,
such as MCP-1 and RANTES and influence over the
macrophage phenotypic balance [69, 70]. This agrees with
the observation that the absence of FcγRIIB induces
increased atherosclerosis development in Ldlr−/− athero-
sclerosis mouse model, as well as increased activation and
expansion of B cells [71]. However, the role of this recep-
tor is not yet clear, since recently it was reported that
FcγRIIB deficiency reduces atherosclerosis in hyperlipid-
emic Apoe−/− mice, as well as induction of T regulatory
cells and increased secretion of atheroprotective cytokines
such as IL10 and TGFβ, which are partially responsible
for the attenuation of the disease [72].
Even though the role of FcR in lipid removal is not clear,
their contribution in atherosclerosis development has
been previously described either directly in lipids clear-
ance or indirectly during inflammation. The role of
FcγRIIB during atherosclerosis is at least partially ex-
plained by the recognition of IgG antibodies directed to
oxLDL antigens, which could result in protective immun-
ity or down regulation of pre-existing proatherogenic im-
mune responses [71]. This is supported by the observation
that human atherosclerosis lesions as well as sera from
these patients, presents IgG deposits directed to oxLDL
[73, 74]. The inhibitory character of FcγRIIB confers the
ability to modulate B cell activity through regulation
of BCR-mediated signaling, controlling proliferation,
class switching, and B cell differentiation to plasma
cells [75, 76], probably regulating the inflammation
observed in atherosclerosis. However, activating FcγR
are also involved in atherosclerosis, including FcγRIA,
FcγRIIA, and FcγRIIIA, which have been described in
aorta lesions from patients with atherosclerosis [66, 68].
SR
SRs are distinguished by their wide ability to recognize
several ligands, such as microbial, environmental, en-
dogenous and self-modified antigens, either by endo-
cytosis or phagocytosis, contributing to the outcome of
the immune system responses. According to their multi-
domain structure, SR are classified in eight different
classes: A, B, C, D, E, F, G and H [77]. In this review, we
mainly focus on CD36 and SR class B type I (SR-BI), due
to their proved expression on B cells and their relevance
in lipid removal involved in atherosclerosis. These recep-
tors belong to class B and D, respectively [43].
Besides macrophages and dendritic cells, other cell
types including B, and some epithelial and endothelial
cells express SR [78]. Specifically in B cells, a differential
expression of some SRs such as CD36 and CD68 has
been described, depending on the B cell subset studied.
According to the differential analysis of gene expression
by DNA microarrays, these receptors are expressed on
marginal zone (MZ) but not on follicular (FO) B cells
[79], even though for example the function of CD68 on
MZ B cells remains to be determined.
CD36
CD36 belongs to the class B SR [80], and is a type III
receptor with two transmembrane domains, an extracel-
lular loop with multiple glycosylation sites and two short
intracellular tails [43]. CD36 in both murine and human
versions, mediates not just the specific uptake of oxLDL,
but also its intracellular accumulation and degradation,
according to experiments with transfected cells with this
molecule [80, 81]. This is also supported by the
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observation that CD36 null mice present a fast and sig-
nificant increase in the levels of circulating cholesterol,
non-esterified free fatty acids and triacylglycerol [82].
Although, the role of CD36 in B cells is not yet clear, it
has been reported to be a specific marker for MZ B cells,
due to the absence in its expression on B1 B cells. Also, it
was reported that its expression could be rapidly induced
on mature B cells, like FO B cells by TLR and CD40
stimulation. However, the lack of CD36 in CD36−/− mice
reveal a minimal effect on mature B cells development,
which is evidenced in the transitional B cells stages [83].
Major effect is observed in plasma cell generation
and specific antibody responses to infectious diseases
in vivo [83, 84]. Just like CD68, differential expression
of CD36 in B cells, could be related with the diverse
roles of B cells subsets in immune responses
mediated by SRs.
In the context of lipid related diseases, it was
shown that the absence of CD36 protects against
atherosclerotic lesion development in Apoe−/− mice,
which approximately developed just a 20% of lesion
assessed by en face analysis of whole aortas, com-
pared with control mice [85–87]. Whereas groups of
triple knockout CD36−/−Msr1−/−Apoe−/− mice, defi-
cient not just for CD36, but also for SR-AI and SR-
AII receptors, which also recognize modified LDL
such as acetylated LDL (AcLDL) and oxLDL, exhib-
ited increased serum cholesterol levels and larger ath-
erosclerotic lesions located in aortic sinus compared
with Apoe−/− mice as controls. This suggests that the
lipid uptake mediated through SR, protected against ath-
erosclerosis lesion formation rather than promote it [88].
Finally, no difference was observed between the size of
aortic lesion in Ldlr−/−CD36−/− and Ldlr−/−CD36+/+ mice
fed with western diet. However, bone marrow transplant
from Ldlr−/−CD36−/− into Apoe−/− mice induced
38.4% less lesion area compared with those receiving
Ldlr−/−CD36+/+ transplant [89]. These contradictory
results could indicate that the role of this receptor is
not only related with aberrant lipid metabolism, but
also with persistent inflammatory milieu probably
modulating disease progression.
SR-BI
SR-BI, belongs to the class B receptors of SR family,
which have a loop structure similar to CD36. This recep-
tor contains two alternative splice variants (SR-BI and
SR-BII), and contrary to CD36 receptor, SR-BI recog-
nizes mainly HDL and is responsible for reverse choles-
terol transport; however it also recognizes modified
lipids, among them oxLDL, as well as native LDL, sug-
gesting that SR-BI could play a role in normal LDL me-
tabolism [90] and could present a selective lipid uptake
from HDL [91, 92].
SR-BI is expressed in different tissues such as adrenal
glands, steroidogenic tissue and hepatocytes, as well as in
different types of cells, like monocytes, macrophages and
dendritic cells [93]. According to experiments evaluating
total spleen RNA derived from C57BL/6 mice, SR-BI as
well as its splice variants, CD36 and macrophage receptor
with collagenous structure (MARCO) are expressed in
these cells [94]. Another observation that suggests a pos-
sible role of SR-BI in B cells, is that the dual engagement
of SR-BI and TLR9 by CpG down regulates IL6 and IL10
cytokines, as well as IgM production [94].
Previously, it has been reported that SR-BI expression
protects against early onset atherosclerosis development
in mouse models of the disease such as Apoe−/− and
Ldlr−/− [95, 96]. SR-BI−/−Apoe−/− mice fed with standard
chow diet developed occlusive coronary artery athero-
sclerosis, as well as significant atherosclerotic lesions,
compared with control mice [97]. It has furthermore
been demonstrated that transplantation of bone marrow
from SR-BI−/− mice into female Ldlr−/− mice, induced a
twofold reduction of the mean atherosclerotic lesion
area after 4 weeks of HFD. According to previous re-
ports, SR-BI in bone marrow derived cells has a dual
role in atherosclerotic lesion development, depending on
disease stage [98]. Recent data from our collaborators
showed that mice with advanced atherosclerosis have a
variety of alterations in the frequency and phenotype of
B lymphocytes, most of which were associated with dys-
lipidemia. This was observed in spleen and aortic tissue,
suggesting the role of B cells in atherosclerosis both as a
systemic and a localized disease [99, 100].
B cells involved in lipid immune responses
through CD1 receptors
CD1
Even though CD1 is not directly involved in lipids recog-
nition/removal, it participates in the antigen presenta-
tion of lipids, leading to immune responses that
contribute with the inflammatory process. This receptors
belong to a family of β2 microglobulin associated pro-
teins related to the MHC class I and II, but encoded by
genes outside the MHC. Humans have five CD1 iso-
forms which divide in three groups; the first one com-
prises CD1a, CD1b and CD1c; the second includes
CD1d, and the third one CD1e molecule. In mice, there
is a single class of CD1 molecule (mCD1d) which is
homologous to human CD1d [101–105].
CD1d
CD1d expression has been described in different cell
types, including B cells, which express low levels of this
marker [106]. In contrast to classical peptide antigen pres-
entation, CD1 molecules have evolved to present lipid
antigens or hydrophobic peptide antigens [107, 108] to T
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cells, activating a specialized T cell subset called iNKT
cells, which express the T cell receptor (TCR) rearrange-
ment Vα14-Jα281 (also known as Jα18 or Jα15) in mice
and Vα24-Jα18 in humans [55, 109]. These TCR mole-
cules recognize exogenous glycosphingolipid antigens
such as α-galactosylceramide (α-GalCer, isolated from
marine sponges), α-glucosylceramides, or diacylglyc-
erol (isolated from the Gram-negative bacteria
Sphingomonas and Borrelia burgdorferi spirochete,
respectively) [39, 110–115].
In human cells, it has been reported that the inter-
action between iNKT and B cells trough CD1d even in
the absence of α-GalCer, promote proliferation of mem-
ory and naive B lymphocytes, as well as Ig production.
One of the hypothesis to explain this, suggests that B
cells express an endogenous glycolipid different to α-
GalCer, associated to CD1d and recognized by iNKT
cells [41, 111]. Interestingly, Kain et al. have showed
the presence of α-linked contaminants by blocking its
stimulatory activity using antagonists, among them
anti-CD1-α-GalCer antibody L363. Also confirming
that β-glucosylceramides have no stimulatory proper-
ties towards NKT cells [116]. However, more recent
studies conclude that β-glucosylceramides primarily
constitute an NKT type II (CD1d-restricted T cells
lacking iTCR) ligand, which display a distinct cytokine
profile and provide robust help to B cells [34]. On
the other hand, interaction of B cells with lipids is
also evidenced by the observation that lipid activated
iNKT cells lead to the activation of B cells. Also, it
has been suggested that iNKT cells can convert tol-
erogenic B cells into immunogenic antigen presenting
cells (APCs), which can generate long-lasting cyto-
toxic immunity; mechanism that could depend on the
expression of functional CD1d [117]. Direct inter-
action of B and iNKT cells induce antibody responses
during humoral immunity, which is an important
mechanism dependent on the expression of CD1d on
B cells [38]. This interaction could participate in the
inflammatory responses that involve lipids removal
and subsequent inflammation, like the one observed
in atherosclerosis. In fact, it has been reported that
the activation of CD1d-restricted iNKT cells exacer-
bates atherosclerosis [118, 119]. Additionally, the rele-
vance of CD1d-restricted NKT cells in atherosclerosis
is demonstrated by a 40% reduction in fatty streaks
formation in CD1d−/−Ldlr−/− mice compared with
competent CD1d Ldlr−/− mice. However, the import-
ance of CD1d on lesion progression is just transitory
and does not significantly affect the inflammatory
cytokine milieu of mature lesions [120].
Also, in other chronic inflammatory disorders such as
autoimmune diseases, recent data indicates that CD1d de-
ficiency worsens autoantibody production and nephritis in
a genetically susceptible lupus mouse model (BWF1)
[121], as well in the hydrocarbon oil-induced model of
lupus nephritis [122]. In parallel, iNKT cells participate in
the regulation of autoantibody production, since autoreac-
tive B cells are selectively reduced in the presence of acti-
vated iNKTs in a CD1d-contact dependent manner [123].
Most recently, it has also been established that inappropri-
ate presentation of CD1d-restricted self-lipids by auto-
immune B cells is a crucial mechanism leading to iNKT
cell hyperactivation, proliferation, and apoptosis in auto-
immune mice [124]. In the same way it has been proposed
that healthy B cells are pivotal for iNKT cell homeostasis,
related to the fact that in healthy donors, B cells are essen-
tial for iNKT cells expansion and activation, conditions
that fail in patients with systemic lupus erythematous
(SLE) due to altered CD1d recycling [125].
Conlusions
Lipid dysregulation is the result of several inadequate
life styles that progress to metabolic changes. This
has huge impact during development and establish-
ment of lipid related diseases, especially in athero-
sclerosis, which underlies the majority of CVDs. In
this sense, immune responses and metabolic regula-
tion are highly integrated, even a slight disruption of
this interaction could lead to a silent but dangerous
systemic imbalance. This is reflected by an elevated
concentration of circulating lipids, due to altered
metabolism of lipids, aberrant intracellular signaling,
as well as unbalanced production of pro and anti-
inflammatory cytokines and the participation of
various immune cells. This miscommunication can
transform into a steady state of inflammation, which
could lead to tissue dysfunction and remodeling.
B cells might play specific roles in chronic inflamma-
tory disorders; however it has been hard to establish
because of its variability in terms of frequency and func-
tionality among disease models, animal strains and diets.
Despite the fact that other cells such as macrophages are
the main subject of study in this area, participation of B
cells in lipid inflammatory conditions is evidenced by
the expression of a variety of receptors that can
recognize foreign, endogenous or self-modified antigens
such as oxidized lipids, which suggests the participation
of B cells in lipotoxicity.
In the early stages of CVDs, hypercholesterolemia
induces the diffusion of LDL particles through the ac-
tivated endothelium, which in turn cause the expres-
sion of adhesion molecules which recruit, arrest and
finally ends in the entrance of immune system cells
to the sub-endothelial space. In mice, it has been re-
ported that cells and soluble factors circulate from
aortic tertiary lymphoid organs (ATLOs), which locate
in the adventitia of diseased vessels. During the
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development of atherosclerotic disease, we speculate
that B cells have an important participation, since the
expression of LDLR contributes with the recognition
of LDL molecules and its antigenic presentation
trough CD1d to iNKTs exacerbates the disease. The
progressive establishment of the inflammatory process
and the presence of these molecules in the sub-
endothelial space, induce its oxidation generating
oxLDL, which are recognized by SR such as CD36,
inducing an increased removal of these molecules. In
parallel, we can find the up regulation of FcγRIIB
receptor that through its inhibitory activity induces
anti-inflammatory responses after the interaction with
immune complexes of IgG and oxLDL, decreasing
inflammation (Fig. 1).
All these observations open a number of possibil-
ities regarding to the clinical application of B cells for
both the early diagnosis and treatment of atheroscler-
osis and other lipid metabolism diseases in humans. B
cells are clearly involved in lipid mediated diseases as
well as in chronic inflammatory conditions, probably
by the recognition of lipids through some of the re-
ceptors mentioned here, but more work needs to be
done in this field.
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